Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Adaptive Biotechnologies believes the adaptive immune system is nature's most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Its proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics, and drug discovery. We have three commercial products, and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
Company profile
Ticker
ADPT
Exchange
Website
CEO
Chad Robins
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Exelixis • Sana Biotechnology • Bio-Techne • Ginkgo Bioworks ...
Former names
Adaptive TCR Corp
SEC CIK
Corporate docs
Subsidiaries
Digital Biotechnologies, Inc. • Adaptive Biotechnologies B.V. ...
IRS number
270907024
ADPT stock data
Analyst ratings and price targets
Current price
Average target
$15.00
Low target
$14.00
High target
$16.00
Scotiabank
Initiated
$15.00
Piper Sandler
Upgraded
$14.00
Morgan Stanley
Maintains
$16.00
Latest filings (excl ownership)
10-Q
2022 Q3
Quarterly report
3 Nov 22
8-K
Adaptive Biotechnologies Reports Third Quarter 2022 Financial Results
3 Nov 22
8-K
Adaptive Biotechnologies Announces Non-Dilutive Royalty Financing with OrbiMed for Up to $250 Million
12 Sep 22
10-Q
2022 Q2
Quarterly report
3 Aug 22
8-K
Adaptive Biotechnologies Reports Second Quarter 2022 Financial Results
3 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
14 Jun 22
10-Q
2022 Q1
Quarterly report
4 May 22
8-K
Adaptive Biotechnologies Reports First Quarter 2022 Financial Results
4 May 22
DEFA14A
Additional proxy soliciting materials
22 Apr 22
DEF 14A
Definitive proxy
22 Apr 22
Transcripts
ADPT
Earnings call transcript
2022 Q3
4 Nov 22
ADPT
Earnings call transcript
2022 Q2
4 Aug 22
ADPT
Earnings call transcript
2022 Q1
4 May 22
ADPT
Earnings call transcript
2021 Q4
16 Feb 22
ADPT
Earnings call transcript
2021 Q3
4 Nov 21
ADPT
Earnings call transcript
2021 Q2
5 Aug 21
ADPT
Earnings call transcript
2021 Q1
6 May 21
ADPT
Earnings call transcript
2020 Q4
25 Feb 21
ADPT
Earnings call transcript
2020 Q3
10 Nov 20
ADPT
Earnings call transcript
2020 Q2
10 Aug 20
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|
| Revenue | ||||
| Cost of revenue | ||||
| Operating income | ||||
| Operating margin | ||||
| Net income | ||||
| Net profit margin | ||||
| Cash on hand | ||||
| Change in cash | ||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 219.99 mm | 219.99 mm | 219.99 mm | 219.99 mm | 219.99 mm | 219.99 mm |
| Cash burn (monthly) | (no burn) | (no burn) | 15.14 mm | 18.55 mm | 14.14 mm | 17.31 mm |
| Cash used (since last report) | n/a | n/a | 60.92 mm | 74.62 mm | 56.87 mm | 69.65 mm |
| Cash remaining | n/a | n/a | 159.07 mm | 145.36 mm | 163.12 mm | 150.34 mm |
| Runway (months of cash) | n/a | n/a | 10.5 | 7.8 | 11.5 | 8.7 |
Institutional ownership, Q3 2022
88.9% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 222 |
| Opened positions | 45 |
| Closed positions | 29 |
| Increased positions | 80 |
| Reduced positions | 58 |
| 13F shares | Current |
|---|---|
| Total value | 903.93 mm |
| Total shares | 127.13 mm |
| Total puts | 71.40 k |
| Total calls | 120.10 k |
| Total put/call ratio | 0.6 |
| Largest owners | Shares | Value |
|---|---|---|
| Viking Global Investors | 29.99 mm | $213.56 mm |
| Vanguard | 11.67 mm | $83.10 mm |
| Matrix Capital Management | 11.57 mm | $82.40 mm |
| BLK Blackrock | 10.12 mm | $72.05 mm |
| ARK Investment Management | 9.34 mm | $66.48 mm |
| CMTDF Sumitomo Mitsui Trust | 4.84 mm | $34.45 mm |
| Nikko Asset Management Americas | 4.84 mm | $33.24 mm |
| Blue Water Life Science Advisors | 3.60 mm | $25.64 mm |
| BLVGF Bellevue | 3.28 mm | $23.35 mm |
| Geode Capital Management | 2.05 mm | $14.60 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 10 Jan 23 | R Mark Adams | Common Stock | Sell | Dispose S | No | Yes | 8.58 | 2,130 | 18.28 k | 113,518 |
| 9 Jan 23 | R Mark Adams | Common Stock | Sell | Dispose S | No | No | 8.5 | 995 | 8.46 k | 115,648 |
| 16 Nov 22 | Kyle Piskel | Common Stock | Sell | Dispose S | No | No | 8.87 | 959 | 8.51 k | 46,706 |
| 16 Nov 22 | Kyle Piskel | Common Stock | Sell | Dispose S | No | No | 8.87 | 307 | 2.72 k | 47,358 |
| 1 Nov 22 | Nitin Sood | Common Stock | Sell | Dispose S | No | Yes | 8 | 31,066 | 248.53 k | 114,505 |
| 10 Oct 22 | R Mark Adams | Common Stock | Sell | Dispose S | No | Yes | 7.13 | 2,284 | 16.28 k | 116,643 |
| 7 Oct 22 | R Mark Adams | Common Stock | Sell | Dispose S | No | No | 7.61 | 841 | 6.40 k | 118,927 |
News
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
5 Jan 23
Scotiabank Initiates Coverage On Adaptive Biotechnologies with Sector Outperform Rating, Announces Price Target of $15
5 Jan 23
Why Venus Concept Shares Are Trading Higher By Over 63%? Here Are 58 Stocks Moving In Wednesday's Mid-Day Session
21 Dec 22
What To Know About Piper Sandler's Upgrade of Adaptive Biotechnologies
21 Dec 22
Benzinga's Top Ratings Upgrades, Downgrades For December 21, 2022
21 Dec 22
Press releases
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2022 Financial Results on February 14, 2023
23 Jan 23
Adaptive Biotechnologies to Present at the 41st Annual J.P. Morgan Healthcare Conference
27 Dec 22
Thinking about buying stock in HTG Molecular Diagnostics, 180 Life Sciences, Six Flags Entertainment, Under Armour, or Adaptive Biotechnologies?
21 Dec 22
Adaptive Biotechnologies Highlights New Data Showcasing the Clinical Utility of clonoSEQ® MRD Testing in Patients with Blood Cancers at the 64th ASH Annual Meeting
10 Dec 22
Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Clinical Utility and Benefit of clonoSEQ® MRD Testing in Blood Cancer Patients at 2022 ASH Annual Meeting
5 Dec 22